Belgian Personal Products Stock News

ENXTBR:CMBT
ENXTBR:CMBTOil and Gas

Cmb.Tech (ENXTBR:CMBT) Valuation Check After VLCC Sale And Recent Share Price Strength

VLCC sale puts fresh focus on Cmb.Tech (ENXTBR:CMBT) Cmb.Tech (ENXTBR:CMBT) has attracted renewed attention after agreeing to sell its two VLCC vessels, Ingrid and Ilma. Delivery is scheduled for Q2 2026, with an expected capital gain of about US$98.2 million. See our latest analysis for Cmb.Tech. The VLCC sale headlines come as Cmb.Tech’s share price has moved to €10.66, with a 30 day share price return of 9.78% and a 90 day gain of 28.43%. The 5 year total shareholder return of 123.89%...
ENXTBR:FAGR
ENXTBR:FAGRHealthcare

A Look At Fagron (ENXTBR:FAGR) Valuation After Recent Steady Share Performance

Fagron overview and recent share performance Fagron (ENXTBR:FAGR) has been on some investors radar after its recent share performance, with the stock showing a 0.2% move over the past day and a 0.7% change over the past week. See our latest analysis for Fagron. Beyond the latest moves, Fagron’s 90-day share price return of 7.49% and 1-year total shareholder return of 15.55% point to steady momentum, echoed by a 54.13% total shareholder return over three years. If this kind of steady...
ENXTBR:OBEL
ENXTBR:OBELWireless Telecom

What Orange Belgium (ENXTBR:OBEL)'s 2025 Profit Rise and Dividend Pause Decision Means For Shareholders

Orange Belgium S.A. has reported its full-year 2025 results, with revenue of €1,963.4 million, net income of €41.3 million, and basic earnings per share from continuing operations of €0.61, alongside a decision not to pay a 2025 dividend to conserve cash. Despite slightly lower revenue than the prior year, Orange Belgium increased net income and marginally surpassed its 2025 EBITDAaL guidance, supported by growth in mobile postpaid and cable customers and continued efficiency gains. We will...
ENXTBR:LOTB
ENXTBR:LOTBFood

Lotus Bakeries (ENXTBR:LOTB) Net Margin Of 12.7% Tests Justification For Premium P/E

Lotus Bakeries (ENXTBR:LOTB) has wrapped up FY 2025 with second half revenue of €697.7 million, basic EPS of €114.31 and net income of €92.9 million, while trailing twelve month revenue sits at about €1.4 billion with EPS of €212.06. The company has seen revenue move from €632.7 million in the second half of 2024 to €657.3 million in the first half of 2025 and €697.7 million in the second half of 2025. EPS over the same periods stepped from €99.12 to €97.74 and then €114.31, setting up a...
ENXTBR:094426466
ENXTBR:094426466Metals and Mining

Is The Market Overlooking Risks In SCR-Sibelco (ENXTBR:094426466) After Recent Share Price Weakness

If you are wondering whether SCR-Sibelco is attractively priced right now, this article walks through how its current share price stacks up against a few different valuation checks. The stock last closed at €4,700.00, with returns of a 2.1% decline over 7 days, a 13.8% decline over 30 days, a 13.8% decline year to date and a 6.0% decline over the past year, which may have some investors reassessing both risk and opportunity around the shares. Recent moves in the share price sit against a...
ENXTBR:WDP
ENXTBR:WDPIndustrial REITs

Assessing Warehouses De Pauw (ENXTBR:WDP) Valuation After Earnings Beat And Renewed Analyst Support

Warehouses De Pauw (ENXTBR:WDP) has drawn fresh attention after reporting full year 2025 results, with gross rents and EBIT slightly ahead of expectations and additional support coming from recent analyst commentary. See our latest analysis for Warehouses De Pauw. The earnings release and recent commentary appear to sit alongside a period of renewed momentum, with a 30 day share price return of 5.86% and 90 day share price return of 11.22%, while the 1 year total shareholder return of 27.16%...
ENXTBR:OBEL
ENXTBR:OBELWireless Telecom

Orange Belgium (ENXTBR:OBEL) Earnings Jump Challenges Bearish Narratives On Profitability

Orange Belgium (ENXTBR:OBEL) FY 2025 Earnings Snapshot Orange Belgium (ENXTBR:OBEL) has just reported its FY 2025 numbers with first half revenue of €962.7 million and basic EPS of €0.04, alongside trailing 12 month revenue of €1.96 billion and EPS of €0.61 that frame the latest run rate. The company recorded revenue of €977.5 million in the first half of 2024 and €1,016.2 million in the second half of 2024, while EPS moved from a loss of €0.20 to a profit of €0.56, before landing at €0.04 in...
ENXTBR:LOTB
ENXTBR:LOTBFood

Assessing Lotus Bakeries (ENXTBR:LOTB) Valuation After Strong 2025 Earnings And Asia Growth Milestones

Why Lotus Bakeries Stock Is in Focus After Its 2025 Results Lotus Bakeries (ENXTBR:LOTB) is back on investors' radar after reporting full year 2025 earnings, including higher sales, net income and earnings per share, helped by its Natural Foods division and new capacity in Thailand. See our latest analysis for Lotus Bakeries. Investors have responded to the 2025 results and the Thailand and India growth plans with a 21.10% 1 month share price return and a 39.87% 3 month share price return,...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Vyvgart Outperformance And Phase 3 Milestones Reframe Argenx Growth Story

Argenx's Vyvgart is significantly outperforming expectations, with recent sales figures pointing to stronger than anticipated demand. The company is preparing for major Phase 3 trial readouts that are expected to clarify the potential of its broader pipeline. These developments are drawing attention from healthcare investors who view Vyvgart as an important contributor to fund performance. argenx (ENXTBR:ARGX) is drawing fresh interest as Vyvgart's performance adds weight to its current...
ENXTBR:094426466
ENXTBR:094426466Metals and Mining

SCR-Sibelco (ENXTBR:094426466) Valuation Check After Mixed Returns And Premium P/E Multiple

Event context and recent return profile SCR-Sibelco (ENXTBR:094426466) has come onto investors’ radar after recent share price moves, with the stock flat over the past day, weaker over the past month, yet slightly higher across the past 3 months. This mixed return profile, alongside an intrinsic discount indicator of 11.43%, is prompting closer attention to how the company’s €2,299.814m revenue and €63.378m net income relate to current market expectations. See our latest analysis for...
ENXTBR:UCB
ENXTBR:UCBPharmaceuticals

What UCB (ENXTBR:UCB)'s First EU-Approved TK2d Therapy Kygevi Means For Shareholders

UCB has received European Union approval for Kygevi to treat thymidine kinase 2 deficiency (TK2d) in patients whose disease began before age 12, marking the first EU-authorized therapy for this rare genetic condition. The decision builds on prior FDA approval and retrospective data showing a very large reduction in risk of death versus untreated TK2d patients, underscoring Kygevi’s medical significance for a small but highly underserved population. We’ll now examine how Kygevi’s first-in-EU...
ENXTBR:KBC
ENXTBR:KBCBanks

Is KBC Group’s (ENXTBR:KBC) Conservative Capital Returns Masking or Revealing Its True Strength?

In recent days, analysts have reiterated positive views on KBC Group, emphasizing its strong profitability, solid capital ratios, and ongoing dividends and buybacks. What stands out is how KBC’s conservative risk approach and continued investment in digital transformation are being framed as core strengths by the analyst community. We’ll now examine how this renewed focus on KBC’s disciplined capital returns shapes the company’s broader investment narrative. Rare earth metals are the new...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

How FDA Priority Review For VYVGART’s Seronegative gMG Use At argenx (ENXTBR:ARGX) Has Changed Its Investment Story

In January, argenx reported continued momentum for its autoimmune drug VYVGART, as the US FDA accepted a priority review of a supplemental biologics license application to extend its use to adults with acetylcholine receptor antibody‑seronegative generalized myasthenia gravis, while the franchise continued to post strong global sales growth in 2025. This combination of regulatory progress and broader clinical ambitions, spanning indications like immune thrombocytopenia, myositis and...
ENXTBR:WDP
ENXTBR:WDPIndustrial REITs

Warehouses De Pauw (ENXTBR:WDP) High Net Margin Poses Fresh Questions For Bulls

Warehouses De Pauw (ENXTBR:WDP) has wrapped up FY 2025 with fourth quarter revenue of €135.6 million and basic EPS of €0.46. This sits against a trailing 12 month picture that includes €545.8 million of revenue and EPS of €1.54. Over recent periods, revenue has moved from €116.1 million and EPS of €0.57 in Q4 2024 to €135.6 million and EPS of €0.46 in Q4 2025. The trailing 12 month net profit margin is reported at 71.4% for the latest year compared with 61.5% a year earlier, and that margin...
ENXTBR:SOLB
ENXTBR:SOLBChemicals

UBS Trim In Solvay Highlights Shifts In Ownership And Valuation

UBS Group AG has fallen below the 3% voting rights threshold in Solvay (ENXTBR:SOLB), according to recent Belgian transparency notifications. The change reflects an adjustment in UBS Group AG's shareholding that may matter for investors tracking Solvay's ownership profile. Solvay, a Belgium based chemicals group, operates in specialty materials, energy transition themes and a wide range of industrial end markets. For you as an investor, shifts in the register involving large institutions...